-
LRRC8A–CAV1 Signaling Drives PDAC Growth
2026-08-25
The reference study identifies a cholesterol-dependent LRRC8A–CAV1 membrane axis that links volume regulation with KRAS/EGFR signaling, ribosome biogenesis, protein synthesis, and pancreatic ductal adenocarcinoma growth. Its combined genetic, pharmacological, proteomic, xenograft, and organoid evidence provides a useful framework for studying how membrane organization supports biosynthetic expansion.
-
MMP-2-Responsive Liposomes for Breast Cancer Immunotherapy
2026-08-24
The reference study developed a cascade-targeted liposome that sequentially delivers the PD-1 pathway-blocking peptide AUNP-12 and the IDO inhibitor NLG919. By coupling MMP-2-responsive release with secondary tumor-cell targeting, the platform remodeled an immunosuppressive breast cancer microenvironment and improved antitumor immune responses.
-
EZ Cap™ Cy5 EGFP mRNA (5-moUTP) Workflow
2026-08-23
Build a dual-channel workflow that separates mRNA uptake from productive translation in the same cells. EZ Cap™ Cy5 EGFP mRNA (5-moUTP) supports nanoparticle screening, macrophage delivery studies, and quantitative transfection optimization with direct Cy5 tracking and EGFP functional readout.
-
RNA Pol II Inhibition and Active Apoptotic Signaling
2026-08-22
Harper et al. show that RNA polymerase II inhibition can trigger apoptosis through active signaling caused by loss of hypophosphorylated RNA Pol IIA, rather than through transcriptional failure alone. Their PDAR framework provides a mechanistic lens for interpreting transcription-targeting drugs and for designing experiments that separate polymerase abundance from transcriptional output.
-
Drosophila Keap1–Lamin Control of Nuclear Architecture
2026-08-21
Carlson and colleagues identify a functional interaction between Drosophila Keap1 and the B-type lamin Dm0, linking xenobiotic and oxidative-response signaling to nuclear lamina organization and heterochromatin distribution. Their perturbation-based evidence suggests that dKeap1 influences chromatin architecture during development, although the direct molecular interface and broader applicability beyond Drosophila remain unresolved.
-
BX795: PDK1 Inhibitor Mechanism and Use
2026-08-21
BX795 is an ATP-competitive PDK1 inhibitor with additional TBK1 and IKKε activity, making it useful for dissecting kinase signaling and innate immune response modulation. Its reported cellular growth-inhibition values are in the micromolar range, so biochemical potency, target selectivity, and cell viability should be interpreted separately.
-
Cefiderocol Activity in Resistant European Non-Fermenters
2026-08-20
This European multicenter study compared cefiderocol with β-lactam/β-lactamase inhibitor combinations against 1,451 clinical Pseudomonas aeruginosa and Acinetobacter spp. isolates, including meropenem-resistant strains. Cefiderocol retained high in vitro activity across most resistant groups, while genomic analysis linked cefiderocol resistance mainly with changes involving iron-uptake pathways and, in many Acinetobacter isolates, acquired β-lactamase genes.
-
HOBt (1-Hydroxybenzotriazole) for Reliable Assays
2026-08-20
This scenario-based guide explains how HOBt (1-Hydroxybenzotriazole), SKU A7025, supports reproducible peptide and amide bond formation before cell viability, proliferation, and cytotoxicity testing. It connects coupling chemistry, hydration and solubility considerations, assay compatibility, data interpretation, and practical product selection without treating HOBt as a direct cell-assay reagent.
-
Spirocyclic POM Analogues Target MmpL3 in TB
2026-08-19
This 2024 Bioorganic Chemistry study identifies spirocyclic phenyl oxazole methyl analogues as a new MmpL3-directed anti-tubercular chemotype. Compound 5c combined submicromolar activity against Mycobacterium tuberculosis and resistant clinical isolates with favorable preliminary ADME, pharmacokinetic, and cytotoxicity profiles, while mutant-generation and docking studies supported MmpL3 as its plausible target.
-
TET2 Metabolite Binding: A Practical STD NMR Protocol
2026-08-19
Zhang, Cheng, and Ye describe an integrated workflow that combines biochemical activity assays with saturation transfer difference NMR to distinguish direct metabolite binding from functional regulation of TET2 dioxygenase. The protocol validates known activators and inhibitors and identifies glyoxylate as a direct TET2-binding metabolite, offering a practical framework for studying metabolism–epigenetics interactions.
-
MLN8237 (Alisertib) for Aurora A Research
2026-08-18
MLN8237 (Alisertib) enables selective Aurora A perturbation across mitotic, apoptosis, and translational cancer biology workflows. This guide connects dose-response design with the newer Aurora A–SAM–trained immunity axis and provides practical troubleshooting for reproducible assays.
-
Biotin-16-UTP: From RNA Labeling to Mechanism
2026-08-17
Biotin-16-UTP enables affinity-based RNA detection, purification, and interaction assays. This guide connects biotin-labeled uridine triphosphate chemistry with mechanistic lncRNA research, using RNASEH1-AS1 as a case study in experimental design.
-
1-methyl Adenosine in UHPLC–MS/MS Purine Profiling
2026-08-17
A 2024 Analytical Chemistry study established a stable isotope-diluted UHPLC–ESI-MS/MS workflow for accurately measuring 12 purine ribonucleosides, including 10 methylated species. Its combination of ammonium bicarbonate-enhanced ionization, isomer-resolving chromatography, methanol extraction, and solid-phase extraction provides a practical analytical foundation for RNA modification research, cellular metabolomics, and biomarker discovery.
-
PD0325901 Workflow for MEK Signaling Studies
2026-08-16
PD0325901 provides a practical way to connect MEK pathway blockade with P-ERK loss, cell-cycle changes, apoptosis, and tumor response. This guide translates the inhibitor into reproducible cancer assays while defining a cautious, hypothesis-driven extension to pluripotency research.
-
Schwartz’s Framework for Measuring Cancer Drug Response
2026-08-15
Hannah R. Schwartz’s dissertation distinguishes drug-induced proliferative arrest from actual cell killing, showing that relative and fractional viability are related but noninterchangeable measures. This framework improves interpretation of cancer drug assays by emphasizing response magnitude, biological composition, and timing rather than relying on a single endpoint.